Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy (COSTAR Lung)

A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel To Dostarlimab + Docetaxel To Docetaxel Alone In Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed On Prior Anti-PD-(L)1 Therapy And Chemotherapy (COSTAR Lung)

This is a multi-center, parallel group treatment, Phase 2/3 open label study evaluating cobolimab in combination with dostarlimab and docetaxel in participants with advanced non-small cell Lung Cancer (NSCLC) who have progressed on prior anti-PD-(L)1 therapy and chemotherapy.

Study Overview

• Status: Active, not recruiting
• Conditions: Lung Cancer, Non-Small Cell
• Intervention / Treatment: Drug: Docetaxel; Biological: Dostarlimab; Biological: Cobolimab

• Study Type: Interventional
• Enrollment (Actual): 758
• Phase: Phase 2; Phase 3

Contacts and Locations

Study Locations

• Argentina
  • Buenos Aires, Argentina, C1426ABP
    • GSK Investigational Site
  • Cipoletti Rio Negro, Argentina, R8324CVE
    • GSK Investigational Site
  • Ciudad Autonoma de Buenos Aire, Argentina, 1425
    • GSK Investigational Site
  • Florida, Argentina, 1602
    • GSK Investigational Site
  • La Rioja, Argentina, F5300COE
    • GSK Investigational Site
  • Pergamino, Argentina, B2700CPM
    • GSK Investigational Site
  • Rosario, Argentina, S2000DBS
    • GSK Investigational Site
  • Viedma, Argentina, R8500ACE
    • GSK Investigational Site
• Australia
  • Queensland
    • South Brisbane, Queensland, Australia, 4101
      • GSK Investigational Site
  • South Australia
    • Ashford, South Australia, Australia, 5037
      • GSK Investigational Site
  • Tasmania
    • Hobart, Tasmania, Australia, 7000
      • GSK Investigational Site
  • Victoria
    • Ballarat, Victoria, Australia, 3350
      • GSK Investigational Site
    • Melbourne, Victoria, Australia, 3004
      • GSK Investigational Site
    • Mount Waverley, Victoria, Australia, 3350
      • GSK Investigational Site
• Belgium
  • Aalst, Belgium, 9300
    • GSK Investigational Site
  • Hasselt, Belgium, 3500
    • GSK Investigational Site
  • Kortrijk, Belgium, 8500
    • GSK Investigational Site
• Brazil
  • Blumenau, Brazil, 89010340
    • GSK Investigational Site
  • Fortaleza, Brazil, 60336-232
    • GSK Investigational Site
  • Porto Alegre, Brazil, 90610000
    • GSK Investigational Site
  • Rio de Janeiro, Brazil, 22250-905
    • GSK Investigational Site
  • Rio de Janeiro, Brazil, 22061080
    • GSK Investigational Site
  • Salvador, Brazil, 40170-110
    • GSK Investigational Site
  • São Paulo, Brazil, 04014-002
    • GSK Investigational Site
• Canada
  • Ontario
    • Greater Sudbury, Ontario, Canada, P3E 5J1
      • GSK Investigational Site
    • Kingston, Ontario, Canada, K7L 2V7
      • GSK Investigational Site
    • Oshawa, Ontario, Canada, L1G 2B9
      • GSK Investigational Site
  • Quebec
    • Greenfield Park, Quebec, Canada, J4V 2H1
      • GSK Investigational Site
    • Montreal, Quebec, Canada, H3T 1E2
      • GSK Investigational Site
• Finland
  • Helsinki, Finland, 00180
    • GSK Investigational Site
  • Kuopio, Finland, 70210
    • GSK Investigational Site
• France
  • Créteil, France, 94010
    • GSK Investigational Site
  • Grenoble, France, 38043
    • GSK Investigational Site
  • Marseille, France, 13009
    • GSK Investigational Site
  • Nice, France, 06189
    • GSK Investigational Site
  • Quimper, France, 29107
    • GSK Investigational Site
  • Rennes, France, 35033
    • GSK Investigational Site
  • Tours, France, 37044
    • GSK Investigational Site
• Germany
  • Augsburg, Germany, 86156
    • GSK Investigational Site
  • Bad Berka, Germany, 99437
    • GSK Investigational Site
  • Berlin, Germany, 12200
    • GSK Investigational Site
  • Bonn, Germany, 53113
    • GSK Investigational Site
  • Cologne, Germany, 51109
    • GSK Investigational Site
  • Dresden, Germany, 01307
    • GSK Investigational Site
  • Essen, Germany, 45147
    • GSK Investigational Site
  • Frankfurt, Germany, 60590
    • GSK Investigational Site
  • Frankfurt, Germany, 60488
    • GSK Investigational Site
  • Halle, Germany, 06120
    • GSK Investigational Site
  • Heidelberg, Germany, 69126
    • GSK Investigational Site
  • Karlsruhe, Germany, 76137
    • GSK Investigational Site
  • München, Germany, 80336
    • GSK Investigational Site
  • München, Germany, 81925
    • GSK Investigational Site
  • Oldenburg, Germany, 26121
    • GSK Investigational Site
• Greece
  • Athens, Greece, 115 27
    • GSK Investigational Site
  • Athens, Greece, 11528
    • GSK Investigational Site
  • Athens, Greece, 12462
    • GSK Investigational Site
  • Athens, Greece, 11526
    • GSK Investigational Site
  • Larissa, Greece, 41100
    • GSK Investigational Site
  • Pylaia Thessaloniki, Greece, 570 01
    • GSK Investigational Site
  • Rio Patras, Greece, 26504
    • GSK Investigational Site
  • Thessaloniki, Greece, 57010
    • GSK Investigational Site
  • Thessaloniki, Greece, 55236
    • GSK Investigational Site
• Italy
  • Ancona, Italy, 60126
    • GSK Investigational Site
  • Avellino, Italy, 83100
    • GSK Investigational Site
  • Florence, Italy, 50134
    • GSK Investigational Site
  • Milan, Italy, 20132
    • GSK Investigational Site
  • Milan, Italy, 20133
    • GSK Investigational Site
  • Monza, Italy, 20900
    • GSK Investigational Site
  • Naples, Italy, 80131
    • GSK Investigational Site
  • Orbassano to, Italy, 10043
    • GSK Investigational Site
  • Perugia, Italy, 06156
    • GSK Investigational Site
  • Siena, Italy, 53100
    • GSK Investigational Site
• Japan
  • Kyoto, Japan, 612-8555
    • GSK Investigational Site
  • Miyagi, Japan, 981-1293
    • GSK Investigational Site
  • Osaka, Japan, 591-8555
    • GSK Investigational Site
  • Yamaguchi, Japan, 755-0241
    • GSK Investigational Site
• Mexico
  • Guadajalara, Mexico, 44280
    • GSK Investigational Site
  • Mexico City, Mexico, 03100
    • GSK Investigational Site
  • Mexico City, Mexico, 06700
    • GSK Investigational Site
  • Mexico City, Mexico, CP 14080
    • GSK Investigational Site
  • Mexico City, Mexico, 03810
    • GSK Investigational Site
  • Monterrey, Mexico, 64460
    • GSK Investigational Site
  • Puebla Puebla, Mexico, 72560
    • GSK Investigational Site
• Netherlands
  • Amersfoort, Netherlands, 3813 TZ
    • GSK Investigational Site
  • Enschede, Netherlands, 7512 KZ
    • GSK Investigational Site
  • Groningen, Netherlands, 9713 GZ
    • GSK Investigational Site
  • Harderwijk, Netherlands, 3844 DG
    • GSK Investigational Site
  • Nijmegen, Netherlands, 6525 GA
    • GSK Investigational Site
  • Utrecht, Netherlands, 3543 AZ
    • GSK Investigational Site
  • Zwolle, Netherlands, 8025 AB
    • GSK Investigational Site
• Poland
  • Bydgoszcz, Poland, 85-796
    • GSK Investigational Site
  • Gdynia, Poland, 81-519
    • GSK Investigational Site
  • Lodz, Poland, 90-338
    • GSK Investigational Site
  • Olsztyn, Poland, 10-357
    • GSK Investigational Site
  • Piła, Poland, 64-920
    • GSK Investigational Site
  • Poznan, Poland, 60-693
    • GSK Investigational Site
• Romania
  • Bucharest, Romania, 013812
    • GSK Investigational Site
  • Craiova, Romania, 200347
    • GSK Investigational Site
  • Craiova Dolj, Romania, 200385
    • GSK Investigational Site
  • Otopeni, Romania, 075100
    • GSK Investigational Site
  • Timișoara, Romania, 300239
    • GSK Investigational Site
• Russia
  • Chelyabinsk, Russia, 454048
    • GSK Investigational Site
  • Moscow Region, Russia, 143423
    • GSK Investigational Site
  • Pushkin, Russia, 196603
    • GSK Investigational Site
  • Saint Petersburg, Russia, 197022
    • GSK Investigational Site
• South Korea
  • Cheongju Chungcheongbuk-do, South Korea, 28644
    • GSK Investigational Site
  • Daegu, South Korea, 42601
    • GSK Investigational Site
  • Gyeonggi-do, South Korea, 10408
    • GSK Investigational Site
  • Pusan, South Korea, 49241
    • GSK Investigational Site
  • Seongnam-si Gyeonggi-do, South Korea, 13620
    • GSK Investigational Site
  • Seoul, South Korea, 06351
    • GSK Investigational Site
  • Seoul, South Korea, 05505
    • GSK Investigational Site
  • Seoul, South Korea, 08308
    • GSK Investigational Site
  • Seoul, South Korea, 03722
    • GSK Investigational Site
  • Suwon Kyunggi-do, South Korea, 443-721
    • GSK Investigational Site
• Spain
  • A Coruña, Spain, 15006
    • GSK Investigational Site
  • Badalona, Spain, 08916
    • GSK Investigational Site
  • Barcelona, Spain, 08036
    • GSK Investigational Site
  • Barcelona, Spain, 08035
    • GSK Investigational Site
  • Burgos, Spain, 09006
    • GSK Investigational Site
  • Córdoba, Spain, 140044
    • GSK Investigational Site
  • Las Palmas de Gran Canar, Spain, 35016
    • GSK Investigational Site
  • Madrid, Spain, 28041
    • GSK Investigational Site
  • Madrid, Spain, 28007
    • GSK Investigational Site
  • Madrid, Spain, 28046
    • GSK Investigational Site
  • Madrid, Spain, 28034
    • GSK Investigational Site
  • Madrid, Spain, 28050
    • GSK Investigational Site
  • Madrid, Spain, 28222
    • GSK Investigational Site
  • Málaga, Spain, 29010
    • GSK Investigational Site
  • Valencia, Spain, 46026
    • GSK Investigational Site
• Sweden
  • Gävle, Sweden, SE-801 87
    • GSK Investigational Site
  • Stockholm, Sweden, 171 64
    • GSK Investigational Site
  • Uppsala, Sweden, SE-751 85
    • GSK Investigational Site
• Taiwan
  • Taipei, Taiwan, 11217
    • GSK Investigational Site
• Thailand
  • Dusit, Thailand, 10300
    • GSK Investigational Site
  • Kho Hong Hat Yai, Thailand, 90110
    • GSK Investigational Site
  • Khon Kaen, Thailand, 40002
    • GSK Investigational Site
  • Pathum Thani, Thailand, 12120
    • GSK Investigational Site
• Turkey (Türkiye)
  • Adana, Turkey (Türkiye), 1120
    • GSK Investigational Site
  • Antalya, Turkey (Türkiye), 07020
    • GSK Investigational Site
  • Izmir, Turkey (Türkiye), 35600
    • GSK Investigational Site
• United Kingdom
  • Cardiff, United Kingdom, CF14 2TL
    • GSK Investigational Site
  • Edinburgh, United Kingdom, EH4 2XU
    • GSK Investigational Site
  • London, United Kingdom, SE1 9RT
    • GSK Investigational Site
  • London, United Kingdom, W1G 6AD
    • GSK Investigational Site
  • Manchester, United Kingdom, M20 4BX
    • GSK Investigational Site
• United States
  • California
    • Fountain Valley, California, United States, 92708
      • GSK Investigational Site
    • Walnut Creek, California, United States, 94596
      • GSK Investigational Site
  • Connecticut
    • Norwich, Connecticut, United States, 06360
      • GSK Investigational Site
  • District of Columbia
    • Washington D.C., District of Columbia, United States, 20422
      • GSK Investigational Site
  • Hawaii
    • Honolulu, Hawaii, United States, 96819
      • GSK Investigational Site
  • Iowa
    • Iowa City, Iowa, United States, 52242
      • GSK Investigational Site
  • Kentucky
    • Edgewood, Kentucky, United States, 41017
      • GSK Investigational Site
  • Nevada
    • Las Vegas, Nevada, United States, 89144
      • GSK Investigational Site
  • New York
    • Mineola, New York, United States, 11501
      • GSK Investigational Site
    • New York, New York, United States, 10016
      • GSK Investigational Site
    • White Plains, New York, United States, 10601
      • GSK Investigational Site
  • Pennsylvania
    • Pittsburgh, Pennsylvania, United States, 15232
      • GSK Investigational Site
    • Pittsburgh, Pennsylvania, United States, 15224
      • GSK Investigational Site
  • South Dakota
    • Sioux Falls, South Dakota, United States, 57105
      • GSK Investigational Site
  • Texas
    • Houston, Texas, United States, 77030
      • GSK Investigational Site
  • Virginia
    • Fredericksburg, Virginia, United States, 22408
      • GSK Investigational Site
  • Washington
    • Tacoma, Washington, United States, 98405
      • GSK Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Participant has histologically or cytologically proven advanced or metastatic NSCLC and only squamous or non-squamous cell carcinoma.
• Participant has received no more than 2 prior lines of therapy for advanced or metastatic disease, which must only include a platinum based (e.g., cisplatin, carboplatin) doublet chemotherapy regimen and an anti-PD-1 or an anti-PD-(L)1 antibody.
• Participant has measurable disease.
• Participant has documented radiographic disease progression on prior platinum based chemotherapy and on or after prior anti-PD-(L)1 therapy.
• Participant agrees to submit an archival formalin-fixed paraffin-embedded (FFPE) tumor tissue specimen that was collected on or after diagnosis of metastatic disease. If archival tissue is not available, the participant must undergo biopsy prior to study entry.
• Participant has an ECOG performance status score of 0 or 1.
• Participant has a life expectancy of at least 3 months.
• Participant has adequate Baseline organ function.
• Participant has recovered from any prior treatment related toxicities.
• Participant agrees to use contraception.

Exclusion Criteria:

• Participant has been previously treated with an anti-PD-[L]1 or anti-programmed death-ligand 2 (anti-PD-[L]2) agent that resulted in permanent discontinuation due to an AE.
• Participant has been previously treated with an anti-T cell immunoglobulin and mucin domain containing 3 (anti-TIM-3) or anti-cytotoxic T lymphocyte associated protein 4 (CTLA 4) agent or docetaxel.
• Participant has a documented sensitizing epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or c-ros oncogene 1 (ROS-1) mutation. Participants whose tumors have not been tested for these driver mutations and therefore who have unknown driver mutation status are not eligible. Participants with squamous histology do not need to be tested for these driver mutations.
• Participant had radiological or clinical disease progression (i.e., worsening performance status, clinical symptoms, and laboratory data) <=8 weeks after initiation of prior anti-programmed cell death protein 1 (anti-PD-1) or anti-PD-L1 antibody. The clinical disease progression should have been confirmed by a subsequent radiological scan.
• Participant has received radiation to the lung that is >30 gray (Gy) within 6 months prior to the first dose of study treatment.
• Participant has completed palliative radiotherapy within 7 days prior to the first dose of study treatment.
• Participant is ineligible if any of the following hepatic characteristics are present: a. Alanine aminotransferase (ALT) >2.5 times upper limit normal (ULN) b. ALT and/or aspartate aminotransferase (AST) >1.5 times ULN concomitant with alkaline phosphatase (ALP) >2.5 times ULN; c. Bilirubin >1 times ULN; d. Current active liver or biliary disease (with the exception of Gilbert's syndrome or asymptomatic gallstones, liver metastases, or otherwise stable chronic liver disease per the Investigator's assessment).
• Participant has known new or progressive brain metastases and/or leptomeningeal metastases. Participants who have received prior therapy for their brain metastases and have radiographically stable central nervous system disease may participate, provided they are neurologically stable for at least 4 weeks before study entry and are off corticosteroids within 3 days prior to the first dose of study treatment.
• Participant has tested positive for the following at Screening or within 3 months before the first dose of study treatment: a. Presence of hepatitis B surface antigen. b. Presence of hepatitis C antibody in the absence of a ribonucleic acid (RNA) test for hepatitis C virus. If a confirmatory RNA test is available, a positive test result will exclude a participant, while a negative test result (indicating absence of active infection) will allow the participant to enter into the study.
• Participant has known human immunodeficiency virus (HIV) (positive for HIV 1 or HIV 2 antibodies).
• Participant has active autoimmune disease that required systemic treatment in the past 2 years, is immunocompromised in the opinion of the Investigator, or is receiving systemic immunosuppressive treatment.
• Participant has symptomatic ascites or pleural effusion. A participant who is clinically stable following treatment of these conditions (including therapeutic thoracentesis or paracentesis) is eligible.
• Participant has current interstitial lung disease, current pneumonitis, or a history of pneumonitis that required the use of glucocorticoids to assist with management.
• Participant has pre-existing peripheral neuropathy that is Grade >=2 by National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0 criteria.
• Participant has received a live vaccine within 30 days of the first dose of study treatment. Seasonal flu vaccines that do not contain live virus and Coronavirus Disease 2019 (COVID-19) vaccines.
• Participant is unable to interrupt aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) for undergoing a biopsy procedure (in cases when a participant does not have an archival biopsy), other than an aspirin dose <=1.3 grams (g) per day, for a 5-day period (8-day) period for long-acting agents, such as piroxicam).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Participants receiving docetaxel	Drug: Docetaxel; Docetaxel will be administered.
Experimental: Participants receiving cobolimab+ dostarlimab+ docetaxel	Drug: Docetaxel; Docetaxel will be administered.; Biological: Dostarlimab; Dostarlimab will be administered.; Biological: Cobolimab; Cobolimab will be administered.
Experimental: Participants receiving dostarlimab+ docetaxel	Drug: Docetaxel; Docetaxel will be administered.; Biological: Dostarlimab; Dostarlimab will be administered.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Survival (OS) (Arm A Versus Arm C)	OS is defined as the time from the date of randomization to the date of death due to any cause.	Up to approximately 234 weeks
Overall Survival (OS) (Arm B Versus Arm C)	OS is defined as the time from the date of randomization to the date of death due to any cause.	Up to approximately 234 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Survival (OS) (Arm A Versus Arm B)	OS is defined as the time from the date of randomization to the date of death due to any cause.	Up to approximately 234 weeks
Overall Response Rate (ORR)	ORR is defined as the percentage of participants who have achieved confirmed complete response (CR) or confirmed partial response (PR) as the best overall response based on Investigator assessment, evaluated using Response Evaluation Criteria in Solid Tumors Criteria (RECIST) version 1.1 . PR: at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (<)10 millimeters (mm).	Up to approximately 234 weeks
Progression Free Survival (PFS)	PFS is defined as the length of time from randomization to the earliest date of assessment of disease progression based on RECIST v1.1 by Investigator assessment or death by any cause, whichever occurs first. Progressive Disease is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start. In addition, the sum has an absolute increase from nadir of 5 mm.)	Up to approximately 234 weeks
Duration of Response (DOR)	DOR is defined as the time from first documented response (CR/PR) until the time of first documentation of disease progression based on RECIST version 1.1 by Investigator assessment or death, whichever occurs first. PR: at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (<)10 millimeters (mm). Progressive Disease is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start).	Up to approximately 234 weeks
Time to Deterioration (TTD) in Lung Cancer	TTD in lung cancer is defined as time from randomization to meaningful deterioration on a composite endpoint of dyspnea, chest pain, and cough, from the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 13 item Lung Cancer Module (EORTC-QLQ-LC13).	Up to approximately 234 weeks
Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score	The EORTC QLQ-C30 includes 30-items with single and multi-item scales. These include five functional scales (physical functioning [PF], role functioning [RF], emotional functioning [EF] cognitive functioning [CF] and social functioning [SF]), three symptom scales (fatigue, nausea/vomiting [N/V] and pain), a global health status (GHS)/ Quality-of-Life (QoL) scale, and six single items (dyspnea, insomnia, appetite loss [AL], constipation, diarrhea and financial difficulties [FD]). Response options are 1 (Not at all) to 4 (Very much). Scores were averaged and transformed to 0 to 100, a high score for functional scales/ GHS/QoL represent better functioning ability or health-related quality-of-life (HRQoL), whereas a high score for symptom scales/ single items represent significant symptomatology. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.	Baseline [Day(D) -1],D1 on Cycle(C)(s) 2,3,4,5,6,9,12,15,18,22,26,30,34,38,42,46,50,54, 58,62,66, End of treatment (EoT- up to approximately(~) 216 weeks), Safety follow up (SFU) at D30 after EOT (~ 220 weeks) & at D90 after EOT (~ 229 weeks)
Change From Baseline in the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 13 Item Lung Cancer Module (EORTC-QLQ-LC13) Assessment	The QLQ-LC13 questionnaire comprises 13 questions assessing lung cancer-associated symptoms (cough, hemoptysis, dyspnea and site-specific pain which includes pain in chest, pain in arm or shoulder and pain in other parts), and treatment-related side effects (sore mouth [SM], dysphagia, peripheral neuropathy [PN] and alopecia). Response options are 1 (Not at all) to 4 (Very much). Scores were averaged and transformed to 0 to 100. Higher scores represent increasing symptom levels. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.	Baseline (D -1),D1 on Cycle(C)(s) 2,3,4,5,6,9,12,15,18,22,26,30,34,38,42,46,50,54, 58,62,66, End of treatment (EoT- up to approximately(~) 216 weeks), Safety follow up (SFU) at D30 after EOT (~ 220 weeks) & at D90 after EOT (~ 229 weeks)
Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Findings	ECGs were recorded after the participants were in a supine or semi-recumbent position (about 30 degrees of elevation) and rested for approximately 2 minutes. ECG findings are summarized as clinically significant change from baseline worst case hierarchy: Yes > No > Not Applicable (NA).	Baseline (Day-1) up to Cycle 1 Day 1
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious AEs (SAEs) and Immune-mediate AEs (imAEs)	A TEAE is any event that was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment. SAE is defined as any untoward medical occurrence that, at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, or is a congenital anomaly/birth defect, other situations which involved medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA dictionary).	Up to 329 weeks
Number of Participants With TEAEs Leading to Death and Treatment Discontinuation	A TEAE is any event that was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment.	Up to 329 weeks
Number of Participants Using Concomitant Medications	Number of participants using concomitant medications will be presented.	Up to 329 weeks
Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline	Blood samples will be collected for the analysis of hematology parameters.	Up to 329 weeks
Number of Participants With Worst Case Clinical Chemistry Results by Maximum Grade Increase Post-Baseline Relative to Baseline	Blood samples will be collected for the analysis of Clinical Chemistry parameters.	Up to 329 weeks
Number of Participants With Worst Case Thyroid Function Results by Maximum Grade Increase Post-Baseline Relative to Baseline	Blood samples will be collected for the analysis of thyroid function	Up to 329 weeks
Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Post-Baseline Relative to Baseline	Urine samples will be collected to analyze urine specific gravity.	Up to 329 weeks
Number of Participants With Worst Case Vital Signs Results Relative to Normal Range Post-Baseline Relative to Baseline	Vital signs will be assessed	Up to 329 weeks
Number of Participants With Maximum Grade Increase Post-Baseline Relative to Baseline in Vital Signs	Vital signs will be assessed and presented	Baseline (Day -1) and Up to 281 weeks
Number of Participants With Indicated Eastern Cooperative Oncology Group (ECOG) Performance Status	Performance status will be assessed using the ECOG performance status scale.	Up to 329 weeks
Number of Participants With Abnormal Physical Examinations	Number of participants with abnormal physical examinations will be presented	Up to approximately 234 weeks

Collaborators and Investigators

• Sponsor: GlaxoSmithKline
• Investigators: Study Director: GSK Clinical Trials, GlaxoSmithKline

Study record dates

Study Major Dates

• Study Start (Actual): December 8, 2020
• Primary Completion (Actual): June 5, 2025
• Study Completion (Estimated): March 30, 2027

Study Registration Dates

• First Submitted: November 30, 2020
• First Submitted That Met QC Criteria: November 30, 2020
• First Posted (Actual): December 7, 2020

Study Record Updates

• Last Update Posted (Actual): July 1, 2026
• Last Update Submitted That Met QC Criteria: June 5, 2026
• Last Verified: June 1, 2026

More Information

Terms related to this study

• Keywords: Docetaxel; Chemotherapy; Dostarlimab; GSK4069889A; GSK4057190A; Cobolimab
• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Respiratory Tract Diseases; Lung Diseases; Respiratory Tract Neoplasms; Thoracic Neoplasms; Lung Neoplasms; Carcinoma, Bronchogenic; Bronchial Neoplasms; Carcinoma, Non-Small-Cell Lung; Organic Chemicals; Hydrocarbons; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Terpenes; Taxoids; Cyclodecanes; Diterpenes; Docetaxel; dostarlimab
• Other Study ID Numbers: 213410; 2020-003433-37 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: IPD for this study will be made available via the Clinical Study Data Request site.
• IPD Sharing Time Frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
• IPD Sharing Access Criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No